

Participant Evaluation - LIVE GYN Symposium

"Neoadjuvant Chemotherapy for Ovarian Cancer - Clinical Considerations and Research Opportunities"

San Diego, CA February 5, 2015

LEGIBLY PRINT OR TYPE YOUR NAME HERE: (REQUIRED in order to receive CME credit)					
For future meetings how would you like to receive your agenda book on the c	day of the sym	posi	um?		
☐ Electronic (link for ipads, computers) ☐ Pape	er book				
Please use the drop down box that best indicates your extent to which, as a result of attending this meeting you are better able to:					
1. Recognize the current evidence regarding NACT in advanced ovarian cancer.	Drop-down List				
2. Apply current strategies to assess functional status and co-morbidities in patients with advanced ovarian cancer and utilize this information to inform decision regarding NACT or primary debulking.	Drop-down List				
3. Outline the evidence regarding various imaging nd biomarker strategies can be utilized to inform decision regarding NACT or primary debulking.	Drop-down List				
4. Knowledge of how future trials incorporating NACYT strategies can be utilized to identify key biologic processed in ovarian cancer and how targeted therapeutics might affect these processes.	Drop-down List				
OVERALL MEETING SUMMARY On a scale of 1(strongly disagree) to 5 (strongly agree) please state your level of agreen with the following statements:	Strong nent < Disag		3		ongly gree > 5
Overall, this activity was excellent		\bigcirc			\bigcirc
2. Program topics and content met the stated objectives		\bigcirc			\bigcirc
3. Content was relevant to your educational needs		\bigcirc			\bigcirc
4. Educational Format was conducive to learning					
5. Acquired knowledge will be applied in your practice environment					\bigcirc
6. Program was fair, objective, and unbiased toward any product or program			\bigcirc		\bigcirc
If you answered #6 with a "strongly disagree" Please explain					

SPEAKERS: Session I - Surgery or NACT in Ovarian Cancer: Factoring in Age, Functional Status and Comorbidity Moderator: William Tew, MD Speakers: Please rate the teaching effectiveness of each Vivian Von speaker William Tew, MD, Deborah Armstrong, MD Kathleen Moore, MD Gruenigen, MD Please use the drop down list 1-Poor - 2- Needs Improvement 3-Fair 4-Great 5- Excellent Effective in presenting material Speaker has expertise on the topic Presentation was well organized and speaker was well-prepared Presentation was fair, objective, and avoided commercial bias or influence Discussion points were stated at the onset and well developed by the speaker SPEAKERS: SESSION II - Assessing Resectability as a guide to choosing NACT or Primary Cytoreducition Moderator: Neil Horowitz, MD Speakers: Please rate the teaching effectiveness of each speaker Dennis Chi, MD Neil Horowitz, MD Michael Birrer, MD, Ph.D. Anil Sood, MD Please use the drop down list 1-Poor - 2- Needs Improvement 3-Fair 4-Great 5- Excellent Effective in presenting material Speaker has expertise on the topic Presentation was well organized and speaker was well-prepared Presentation was fair, objective, and avoided commercial bias or influence Discussion points were stated at the onset and well developed by the speaker **Young Investigators Presentations** Speakers: Please rate the teaching effectiveness of each speaker Please use the drop down list Whitney Graybill, MD Lilian Gien, MD 1-Poor - 2- Needs Improvement 3-Fair 4-Great 5-Excellent Effective in presenting material Speaker has expertise on the topic Presentation was well organized and speaker was well-prepared Presentation was fair, objective, and avoided commercial bias or influence

Discussion points were stated at the onset and well developed by the

speaker

Speakers: Please rate the teaching eff Please use the drop dow 1-Poor - 2- Needs Improvement		Barbara Conley, MD	Robert Burger, MD	Michael Bookman, MD	Michael Sill, MD, Ph.	
Effective in presenting ma	terial					
Speaker has expertise on th	ne topic					
Presentation was well organized and speaker was well- prepared						
Presentation was fair, objective, and avoided commercial bias or influence						
Discussion points were stated at the onset and well developed by the speaker						
What strategies/chan	nges do you plan to imp	Patient counse enrollment in	eling and	Share with ot	hers in my practice on learned in this	
Increase screening		This activity wi		I gained new strategies/skills from this activity		
Other						
Do you anticipate an	y BARRIERS to your imp	lementing any cha	anges to your pra	ctice? (Mark all th	nat apply)	
☐ Knowledge ☐ N	lo Barriers	ective Policy is	sues		imbursment Issues Funding	
☐ Other How would you com	pare your educational e	experience with ot	her CME activitie	s in the past 12 m	nonths	
Excellent	☐ Great	☐ Neutral	☐ Needs Imp	rovement I	Needs serious improvement	
☐ Other						
Do you have any sugges topics that would enhan objectives						

Thank You eval 09/15